Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.53 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.53 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.53 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3911066 | 1.00 | GPR84 (0.55) | GPR84FFAR1ACE2ALDH1A1MAPT | |
| SCHEMBL5027014 | 1.00 | GPR84 (0.55) | GPR84FFAR1ACE2ALDH1A1MAPT | |
| SCHEMBL3303784 | 1.00 | GPR84 (0.55) | GPR84FFAR1ACE2ALDH1A1MAPT | |
| SCHEMBL3304320 | 1.00 | GPR84 (0.55) | GPR84FFAR1ACE2ALDH1A1MAPT | |
| SCHEMBL3913154 | 1.00 | GPR84 (0.55) | GPR84FFAR1ACE2ALDH1A1MAPT | |
| SCHEMBL2211128 | 1.00 | GPR84 (0.55) | GPR84FFAR1ACE2ALDH1A1MAPT | |
| SCHEMBL3902890 | 1.00 | GPR84 (0.55) | GPR84FFAR1ACE2ALDH1A1MAPT | |
| SCHEMBL3904059 | 1.00 | GPR84 (0.55) | GPR84FFAR1ACE2ALDH1A1MAPT | |
| SCHEMBL2488736 | 1.00 | GPR84 (0.55) | GPR84FFAR1ACE2ALDH1A1MAPT | |
| SCHEMBL8358553 | 1.00 | GPR84 (0.55) | GPR84FFAR1ACE2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119136789-A | Method for producing nucleic acid-encapsulated lipid nanoparticle, method for producing pharmaceutical composition comprising same, and method for introducing nucleic acid into cells or target cells | 日油株式会社 | 2024-12-13 | — | — | CN | disclosed |
| CN-117479963-A | PEG lipids and lipid nanoparticles | 盖纳万科学有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-10100008-B2 | Immunostimulating agent | AJINOMOTO CO., INC. (JP) | 2018-10-16 | — | — | US | disclosed |
| EP-3134385-A1 | IMMUNOSTIMULATING AGENT | Ajinomoto Co., Inc. (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-20170036999-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2017-02-09 | — | — | US | disclosed |
| WO-2015163488-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2015-10-29 | — | — | WO | disclosed |
| EP-2123662-B1 | TREHALOSE COMPOUND, PROCESS FOR PRODUCTION OF THE COMPOUND, AND IMMUNO-STIMULATIVE AGENT COMPRISING THE COMPOUND | GLYTECH INC (JP) | 2013-12-04 | — | — | EP | disclosed |
| CN-103068807-A | Method for producing phenyl-substituted heterocyclic derivative by means of coupling method using a palladium compound | TEIJIN PHARMA LTD | 2013-04-24 | — | — | CN | disclosed |
| CN-102203110-A | Trehalose compound, method for producing same, and pharmaceutical product containing the compound | OTSUKA CHEMICAL CO LTD | 2011-09-28 | — | — | CN | disclosed |
| US-20100093993-A1 | TREHALOSE COMPOUND, PROCESS FOR PRODUCTION OF THE COMPOUND, AND IMMUNO-STIMULATIVE AGENT COMPRISING THE COMPOUND | OTSUKA CHEMICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2123662-A1 | TREHALOSE COMPOUND, PROCESS FOR PRODUCTION OF THE COMPOUND, AND IMMUNO-STIMULATIVE AGENT COMPRISING THE COMPOUND | Otsuka Chemical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170036999-A1 | IMMUNOSTIMULATING AGENT | MYD88, IFNG, ICOS | GPR84 1412/4885FFAR1 2688/4885ACE2 1715/4885 |
| US-10100008-B2 | Immunostimulating agent | MYD88, IFNG, ICOS | GPR84 1412/4885FFAR1 2688/4885ACE2 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.